SEC Filing Document

Company: BIOVENTRIX, INC.
Ticker: 
CIK: 1283259
Filing Type: S-1/A
Document Type: EX-1.1
Date Filed: 2026-03-18
Accession Number: 0001493152-26-010642
Exchange: 
SIC Code: 3841
SIC Description: Surgical & Medical Instruments & Apparatus
URL: https://www.sec.gov/Archives/edgar/data/1283259/000149315226010642/ex1-1.htm

Chunk 20 of 21
Word Count: 809
Character Count: 5154

Document Content:

to trial by jury in any legal proceeding arising out of or relating to this Agreement or the transactions contemplated hereby. Execution in Counterparts. This Agreement may be executed in one or more counterparts, and by the different parties hereto in separate counterparts, each of which shall be deemed to be an original, but all of which taken together shall constitute one and the same agreement, and shall become effective when one or more counterparts has been signed by each of the parties hereto and delivered to each of the other parties hereto. Electronic signatures complying with the New York Electronic Signatures and Records Act (N.Y. State Tech. §§ 301-309), as amended from time to time, or other applicable law will be deemed original signatures for purposes of this Agreement. Delivery of a signed counterpart of this Agreement by facsimile or email/pdf transmission shall constitute valid and sufficient delivery thereof.

Waiver, etc. The failure of any of the parties hereto to at any time enforce any of the provisions of this Agreement shall not
be deemed or construed to be a waiver of any such provision, nor to in any way affect the validity of this Agreement or any provision
hereof or the right of any of the parties hereto to thereafter enforce each and every provision of this Agreement. No waiver of any breach,
non-compliance or non-fulfillment of any of the provisions of this Agreement shall be effective unless set forth in a written instrument
executed by the party or parties against whom or which enforcement of such waiver is sought; and no waiver of any such breach, non-compliance
or non-fulfillment shall be construed or deemed to be a waiver of any other or subsequent breach, non-compliance or non-fulfillment.

[Signature
Page Follows]

the foregoing correctly sets forth the understanding between the Underwriters and the Company, please so indicate in the space provided
below for that purpose, whereupon this letter shall constitute a binding agreement between us.

Very
truly yours,

BIOVENTRIX,
INC.

Name:	David
Richmond

Title:	Co-Chief
Executive Officer

Confirmed
as of the date first written above mentioned, on behalf of itself and as Representative of the underwriters named on Schedule 1
hereto:

THE
BENCHMARK COMPANY, LLC

Name:	John
J. Borer III

Title:	Senior
Managing Director

[SIGNATURE
PAGE]

BIOVENTRIX,
INC. – UNDERWRITING AGREEMENT

SCHEDULE

Underwriter Total Number of Firm Shares to be Purchased Total Number of Option Shares Subject to Over-Allotment Option

The Benchmark Company, LLC [—] [—]

TOTAL [—] [—]

SCHEDULE

Pricing
Information

Number
of Firm Shares: [—]

Public
Offering Price per Share: $[—]

Underwriting
Discount per Share: 7%

Proceeds
to Company per Share (before expenses): $[—]

SCHEDULE

Issuer
General Use Free Writing Prospectuses

None.

SCHEDULE

Written
Testing-the-Waters Communications

None.

SCHEDULE

List
of Lock-Up Parties

1.	David
Richmond

2.	Steven
Chartier

Ori Ben-Yehuda

4.	Mark
Ravich

Rishi Puri

William Abraham

7.	Michael
Taglich

8.	RBI
BioVentrix LLC

9.	RBI
Opportunities Fund LLC

10.	RBI
BV Private Investment

11.	RBI
Private Investment III LLC

12.	RBI
Opportunities Fund II

13.	David
Richmond & Stephanie Richmond

14.	RBI
Private Investment I LLC

15.	Richmond
Brothers Inc.

16.	Taglich
Brothers Inc.

17.	Michael
N. Taglich & Claudia Taglich

18.	Claudia
Ruggiero Taglich

19.	Michael
Taglich C/F Amanda Taglich UTMA NY

20.	Michael
Taglich C/F Lucy Taglich UTMA NY

21.	Michael
Taglich C/F Stella Taglich UTMA NY

22.	Michael
N. Taglich Keogh Account

23.	Michael
Taglich TTEE Hope A Taglich Supplemental Needs Trust UAD 8/23/17

24.	Bioventrix
investors LLC

25.	Mark
Ravich Irrevocable Trust

26.	Mark
Ravich Revocable Trust

27.	Mark
Ravich TTEE Mark Ravich Irrevocable Trust UAD 11/05/18

28.	Mark
H. Ravich TTEE Revocable Trust of Mark H. Ravich UAD 10/08/19

29.	Norman
and Sally Ravich Family Trust

30.	Mark
Ravich TTEE Cindy Libman Irrevocable Trust UAD 11/05/18

31.	Mark
H. Ravich TTEE Norman & Sally Ravich Family Trust UAD 12/24/92

32.	Alexander
Coleman Ravich 1991 Irrevocable Trust

33.	Alyssa
Danielle Ravich 1991 Irrevocable Trust

34.	Ilyne
Ravich

Exhibit

[Form
of lock up]

Exhibit

Form
of Press Release

BIOVENTRIX,
INC.

[Date]

BioVentrix,
Inc. (the “Company”) announced today that The Benchmark Company, LLC, acting as representative for the underwriters
in the Company’s recent public offering of _______ shares of the Company’s common stock, is [waiving] [releasing] a lock-up
restriction with respect to _________ shares of the Company’s common stock held by [certain officers or directors] [an officer
or director] of the Company. The [waiver] [release] will take effect on _________, 20___, and the shares may be sold on or after such
date.

This
press release is not an offer or sale of the securities in the United States or in any other jurisdiction where such offer or sale is
prohibited, and such securities may not be offered or sold in the United States absent registration or an exemption from registration
under the Securities Act of 1933, as amended.

Exhibit

[Form
of warrant]